MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing a comprehensive array of 18 unique gene transcripts. Our algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility, allowing MPS2 to be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference. Receive individualized reports with results tailored to unique patient and clinical context.